Search

Blog

Life in hematology is exciting and poses many challenges, rewards and surprises. Follow our blog and be entertained, informed and inspired!

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Read more

Statement of Solidarity after Earthquake in Morocco

On behalf of the European Hematology Association, I would like to express my deepest condolences and heartfelt support to the people of Morocco who have been affected by the recent earthquake.

Read more

New HemaSphere publication on IVDR implementation

The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…

Read more